Pulmonary Hypertension Overview And Treatment
Settings
This quiz discusses the pathophysiology of pulmonary hypertension and the treatment options.
- 1.Which of the following regarding pulmonary hypertension (PH) is FALSE?
- A.
PH has many underlying etiologies
- B.
The disease affects the left side of the heart
- C.
The hemodynamic definition of PH is a mean pulmonary arterial pressure (PAP) greater than or equal to 25 mmHg
- D.
Pulmonary arterial hypertension (PAH) is a subset of PH
- 2.
- A.
The disease affects men much more than women
- B.
Non-specific symptoms such as fatigue and edema present clinically
- C.
Catheterization is required when PH is suspected
- D.
Underlying causes and PCWP or LVEDP are evaluated
- 3.
- A.
Vasoconstriction is an issue
- B.
Vascular wall remodeling is an issue
- C.
There is a cure for PAH
- D.
The balance of vasoconstriction and vasodilation may indicate PAH
- 4.All of the following are true regarding calcium channel blockers (CCBs) in PAH EXCEPT
- A.
CCBs have a selective effect on vascular smooth muscle
- B.
Normal physiologic doses are sufficient for treatment purposes
- C.
Adverse effects must be considered
- D.
Long-term clinical response is less than 10%
- 5.
- A.
The drug is a prostacyclin analog
- B.
There are two products: Flolan and Veletri
- C.
The drug improves mortality
- D.
The drug is selective
- 6.Which of the following regarding treprostinil is FALSE?
- A.
It has a longer half-life than epoprostenol
- B.
It is also shown to have a survival benefit
- C.
It has a higher cost than epoprostenol
- D.
It is stable at room temperature without a need for a back-up cassette.
- E.
It is a prostacyclin analog
- 7.Treprostinil, similar to epoprostenol, has two products.
- A.
True
- B.
False
- 8.Regarding iloprost, which of the following is FALSE?
- A.
It is a prostacyclin analog
- B.
It is approved for PAH WHO class 3 or 4 symptoms
- C.
Very few doses are given per day
- D.
There is a significant improvement in 6MWD and hemodynamics
- 9.
- A.
It is an ET-1 receptor agonist
- B.
It is safe to use in pregnant women
- C.
It is highly selective for the endothelin A (ETa) receptor
- D.
It has many drug interactions
- 10.Which of the following regarding ambrisentan is FALSE?
- A.
It is a non-selective ETa antagonist
- B.
Teratogenicity is an issue
- C.
Drug interactions are still concerning
- 11.All of the following are true regarding macitentan EXCEPT
- A.
It is safe to use in pregnant women
- B.
It is a tissue selective ET-1 receptor antagonist
- C.
Hepatotoxicity is a concern
- D.
Drug interactions are a cocnern
- 12.Which of the following statements regarding the comparison between sildenfail and tadalafil in the context of PAH is FALSE?
- A.
Sildenafil is shorter-acting while tadalafil is longer-acting
- B.
Sildenafil is TID dosing while tadalafil is QD dosing
- C.
Flushing and hypotension are two concerns with both drugs
- D.
Exercise ability is improved with both drugs
- E.
Nitrates can be safely used with both drugs
- 13.The following statements are true regarding riociguat EXCEPT
- A.
It is a soluble guanylate cyclase (sGC) stimulator
- B.
It can be used in patients with renal failure
- C.
Teratogenicity and hepatotoicity are concerns
- D.
There are many drug interactions
- 14.Which of the following correctly represents the target INR range for a patient with PAH on warfarin?
- A.
1.0 - 2.0
- B.
1.5 - 2.5
- C.
2.0 - 3.0
- D.
2.5 - 3.5
- 15.Which of the following regarding the treatment of PAH is FALSE?
- A.
There is a large amount of long-term data for the therapies of PAH
- B.
Prostacyclin dosage forms must be considered
- C.
Costs and convenience must be considered
- D.
Pharmacists are important in the therapy
- 16.What can pharmacists contribute in the therapy of PAH?
- A.
Medication safety
- B.
Optimizing medical regimens
- C.
Patient education and adherence
- D.
Quality improvement
Back to top